Melanomas in children and adolescents: Clinicopathologic features and survival outcomes

Affiliations

¹ Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Department of Dermatology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
² Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Department of Tissue Oncology and Diagnostic Pathology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia.
³ Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
⁴ Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
⁵ Department of Dermatology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
⁶ Department of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
⁷ Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Department of Tissue Oncology and Diagnostic Pathology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
⁸ Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia. Electronic address: john.thompson@melanoma.org.au.
⁹ Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
¹⁰ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, University Utrecht, Utrecht, the Netherlands.

PMID: 36509217
DOI: 10.1016/j.jaad.2022.08.067

Melanomas in children and adolescents: Clinicopathologic features and survival outcomes

Mary-Ann El Sharouni et al. J Am Acad Dermatol. 2023 Mar.

. 2023 Mar;88(3):609-616.

doi: 10.1016/j.jaad.2022.08.067. Epub 2022 Dec 9.

Authors

Affiliations

¹ Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Department of Dermatology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
² Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Department of Tissue Oncology and Diagnostic Pathology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia.
³ Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
⁴ Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
⁵ Department of Dermatology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
⁶ Department of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
⁷ Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Department of Tissue Oncology and Diagnostic Pathology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
⁸ Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia. Electronic address: john.thompson@melanoma.org.au.
⁹ Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
¹⁰ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, University Utrecht, Utrecht, the Netherlands.

PMID: 36509217
DOI: 10.1016/j.jaad.2022.08.067

Abstract

Background: Melanomas in the first 2 decades of life are uncommon and poorly understood.

Objective: To assess clinicopathologic features and survival of children (≤11 years) and adolescents (12-19 years) diagnosed with melanoma.

Methods: A pooled cohort of 514 patients was analyzed (397 Dutch, 117 Australian; 62 children, 452 adolescents). Pathology reports were reevaluated to determine melanoma subtypes. Multivariable Cox models were generated for recurrence-free survival (RFS) and overall survival (OS).

Results: Melanoma subtypes were conventional melanoma (superficial spreading, nodular, desmoplastic, and acral lentiginous), spitzoid melanoma, and melanoma associated with a congenital nevus in 428, 78, and 8 patients, respectively. Ten-year RFS was 91.5% (95% confidence interval [CI], 82.4%-100%) in children and 86.4% (95% CI, 82.7%-90.3%) in adolescents (P = .32). Ten-year OS was 100% in children and 92.7% (95% CI, 89.8%-95.8%) in adolescents (P = .09). On multivariable analysis possible only for the adolescent cohort due to the small number of children, ulceration status, and anatomic site were associated with RFS and OS, whereas age, sex, mitotic index, sentinel node status and melanoma subtype were not. Breslow thickness >4 mm was associated with worse RFS.

Limitations: Retrospective study.

Conclusions: Survival rates for children and adolescents with melanomas were high. Ulceration, head or neck location and Breslow thickness >4 mm predicted worse survival in adolescents.

Keywords: adolescence; age; children; melanoma; survival.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest RAS has received fees for professional services from F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Merck Sharp & Dohme, GlaxoSmithKline, Bristol-Myers Squibb, Dermpedia, Novartis, Myriad, NeraCare and Amgen. JFT has received honoraria for advisory board participation from GSK, Merck Sharpe & Dohme Australia, Provectus Inc and Bristol Myers Squibb Australia, and travel and conference expenses from GSK, Provectus Inc and Novartis. The other authors have no conflicts to disclose.

Comment in

Estrogen could also play a key role in the development of pediatric melanoma.
Magnaterra E, Zuccaro B, Magliulo M, Venturi F, Silvestri F, Gola M, De Giorgi V. Magnaterra E, et al. J Am Acad Dermatol. 2023 Aug;89(2):e95-e96. doi: 10.1016/j.jaad.2023.01.051. Epub 2023 Mar 20. J Am Acad Dermatol. 2023. PMID: 36940797 No abstract available.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Melanomas in children and adolescents: Clinicopathologic features and survival outcomes

Affiliations

Melanomas in children and adolescents: Clinicopathologic features and survival outcomes

Authors

Affiliations

Abstract

Conflict of interest statement

Comment in

MeSH terms

LinkOut - more resources

Full Text Sources

Medical